Active Ingredients: Orlistat
Study design and assignment of subjects. AE, adverse event; tid, 3 times daily.
Measurements Clinic visits were scheduled weekly for the first 2 mo of the 6-mo lead-in weight-loss period and every 2 wk thereafter.
During the 1-y treatment period, subjects were seen on day 1, at 2-wk intervals during month 1, every month between months 1 and 5, and every 2 mo thereafter.
Body weight was measured at every clinic visit.
Fasting serum glucose and insulin concentrations were also measured at these visits, with one additional measurement during both the 6-mo lead-in weight-loss period and the 1-y treatment period.
The pharmacodynamic effect of orlistat was assessed by measuring fecal fat content.Conclusion: The use of orlistat during with 120 mg orlistat 3 times weight readjustment and facilitates long-term improvement in obesity-related disease risk factors. Results: After 1 y, subjects treated periods of attempted weight maintenance minimizes daily regained less weight than did placebo-treated subjects 32.
Fecal collections were analyzed by Medi-Lab Bioprofil, Copenhagen. All clinical complaints during the 6-mo lead-in weight-loss period and adverse events during the 1-y treatment period were recorded.
To ensure consistency of gastrointestinal event reporting between study centers, a dictionary of standard terms was used to describe changes in defecation patterns.
Statistical analysis Efficacy analyses were performed on the intent-to-treat population, which consisted of subjects who received at least one dose of study medication during the 1-y treatment phase and for whom at least one body weight measurement was taken before and after random assignment.
The safety analysis population included all subjects who had received at least one dose of medication in a double-blind fashion and had at least one follow-up safety evaluation.
For statistical analysis, both observed and derived last observation carried forward data were used.
However, all reported data were actual observed rather than derived values, whereas the technique of carrying forward the last observation was applied only for analyses of statistical significance. The significance of between-group differences for percentage regain of lost weight was tested by applying analysis of covariance ANCOVA to the 1-y treatment period 15.
The analysis was applied to the change in body weight during the 1-y treatment period, expressed as a percentage of the weight lost during the 6-mo lead-in weight-loss period, and weight-loss during the 6-mo lead-in weight-loss period was used as the covariate.
What is the difference between Xenical and Orlistat? Xenical contains the active ingredient Orlistat.
Orlistat is also the name of the less expensive brand of Xenical. Both medications are medically equivalent.
They both contain the same active ingredient and the same amount of it. However, Orlistat is available at a lower price.
All generic medications available in the UK have to demonstrate equivalency and that they have the same effect in the body as the original brand before they can be sold.
Generic medicines are equally effective as the original. If you have been advised to take a multivitamin preparation, you should take it at bedtime or two hours after taking Xenical The active substance is orlistat.
Each capsule contains 120 mg of orlistat. The other ingredients are microcrystalline cellulose E 460, sodium starch glycolate type A, povidone E 1201, sodium laurilsulfate and talc.
The capsule shell consists of gelatine, indigo carmine E 132, titanium dioxide E 171 and edible printing ink. Side Effects of Xenical With any medication you take, there is always a risk of side effects.